Peeling Back The Layers: Exploring ADMA Biologics Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed evaluations of ADMA Biologics (NASDAQ:ADMA) over the past three months, with a majority being bullish. The average 12-month price target has increased to $10.58, reflecting a 23.31% rise from the previous target. Key analysts have raised their price targets, indicating positive sentiment towards the company's future performance.
June 20, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have shown a predominantly bullish sentiment towards ADMA Biologics, with the average 12-month price target increasing by 23.31% to $10.58. Key analysts from firms like Mizuho, Raymond James, and Cantor Fitzgerald have raised their price targets, indicating a positive outlook for the company's stock.
The majority of analysts have raised their price targets for ADMA Biologics, indicating a positive outlook. The average price target has increased significantly, suggesting that the stock is expected to perform well in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100